LON:RENE ReNeuron Group Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 28.50 0.00 (0.00%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range 28.11▼ 29.1050-Day Range 28.50▼ 4152-Week Range 25▼ 135Volume119,213 shsAverage Volume316,193 shsMarket Capitalization£16.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address RENE Stock Forecast (MarketRank)Overall MarketRank™1.00 out of 5 starsAnalyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ReNeuron Group. Previous Next 5.0 Community Rank Outperform VotesReNeuron Group has received 187 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReNeuron Group has received 60 “underperform” votes. (Add your “underperform” vote.)Community SentimentReNeuron Group has received 75.71% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote “Outperform” if you believe RENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReNeuron Group does not currently pay a dividend.Dividend GrowthReNeuron Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ReNeuron Group insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ReNeuron Group is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ReNeuron Group is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReNeuron Group has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ReNeuron Group (LON:RENE)ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More RENE Stock News HeadlinesJune 8, 2022 | americanbankingnews.comReNeuron Group (LON:RENE) Stock Crosses Below 50-Day Moving Average of $35.94April 13, 2022 | marketwatch.comStem Cell Market Size Analysis Report 2022 by Manufacturing Base Distribution, Sales Area and Product Type by Player and Forecasts to 2029March 30, 2022 | finance.yahoo.comReNeuron Group PLC (RQE1.SG)March 1, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional UK£36k as ReNeuron Group plc (LON:RENE) drops to UK£17mFebruary 11, 2022 | marketwatch.comReNeuron CEO Olav Hellebo Steps DownJanuary 18, 2022 | lse.co.ukReNeuron shares dive as it drops retinitis pigmentosa trialsJanuary 18, 2022 | marketwatch.comReNeuron to Exit Retinitis Pigmentosa Therapy Trials; Shares DiveJanuary 11, 2022 | lse.co.ukReNeuron re-appoints Randolph Corteling in senior research roleDecember 19, 2021 | markets.businessinsider.comReNeuron Group plc : Director DeclarationOctober 26, 2021 | finance.yahoo.comHere's Why We're Not At All Concerned With ReNeuron Group's (LON:RENE) Cash Burn SituationOctober 23, 2021 | lse.co.ukDirector dealings: Reneuron Group non-executive makes share purchaseOctober 21, 2021 | lse.co.ukDIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 sharesOctober 11, 2021 | finanznachrichten.deEdison Investment Research Limited: ReNeuron Group (RENE): Extension Trial to Produce Data in Q122See More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:RENE CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees38Year FoundedN/ACompany Calendar Last Earnings7/20/2020Today6/24/2022Next Earnings (Estimated)7/04/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.49 Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual Sales£274 thousand Price / Sales59.35 Cash FlowGBX 30.60 per share Price / Cash Flow0.93 Book ValueGBX 24.90 per share Price / Book1.14Miscellaneous Outstanding Shares57,064,000Free FloatN/AMarket Cap£16.26 million OptionableNot Optionable BetaN/A ReNeuron Group Frequently Asked Questions How has ReNeuron Group's stock price performed in 2022? ReNeuron Group's stock was trading at GBX 82 at the beginning of the year. Since then, RENE shares have decreased by 65.2% and is now trading at GBX 28.50. View the best growth stocks for 2022 here. When is ReNeuron Group's next earnings date? ReNeuron Group is scheduled to release its next quarterly earnings announcement on Monday, July 4th 2022. View our earnings forecast for ReNeuron Group. How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) issued its earnings results on Monday, July, 20th. The company reported ($35.90) EPS for the quarter, topping analysts' consensus estimates of ($50.20) by $14.30. View ReNeuron Group's earnings history. Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the following people: Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D, Exec. Chairman (Age 68)Dr. John David Sinden B.A., BA, M.A., MA, Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 71)Ms. Catherine Isted A.C.M.A., CFO & Exec. DirectorMs. Suzanne Hancock, Head of OperationsDr. Stefano Pluchino, Chief Scientific OfficerMr. Shaun Stapleton, Head of Regulatory Affairs and VP of Regulatory Affairs & PharmacovigilanceJohn Hawkins, Company Sec. Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include Sirona Biochem (SBM), Resverlogix (RVX), Heat Biologics (HTBX), Microbix Biosystems (MBX), Medigene (MDG1), Burcon NutraScience (BU), C4X Discovery (C4XD), ProMIS Neurosciences (PMN), Acasti Pharma (ACST), 4basebio (4BB), Asterias Biotherapeutics (AST), Emerald Health Therapeutics (EMH), Ceapro (CZO), OKYO Pharma (OKYO) and Helix BioPharma (HBP). View all of RENE's competitors. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF). What is ReNeuron Group's stock symbol? ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE." How do I buy shares of ReNeuron Group? Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is ReNeuron Group's stock price today? One share of RENE stock can currently be purchased for approximately GBX 28.50. How much money does ReNeuron Group make? ReNeuron Group (LON:RENE) has a market capitalization of £16.26 million and generates £274 thousand in revenue each year. How many employees does ReNeuron Group have? ReNeuron Group employs 38 workers across the globe. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The official website for ReNeuron Group is www.reneuron.com. The company can be reached via phone at +44-20-38198400. This page (LON:RENE) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
